WO2000055345A3 - Therapy of cancer by insect cells containing recombinant baculovirus encoding genes - Google Patents

Therapy of cancer by insect cells containing recombinant baculovirus encoding genes Download PDF

Info

Publication number
WO2000055345A3
WO2000055345A3 PCT/US2000/007200 US0007200W WO0055345A3 WO 2000055345 A3 WO2000055345 A3 WO 2000055345A3 US 0007200 W US0007200 W US 0007200W WO 0055345 A3 WO0055345 A3 WO 0055345A3
Authority
WO
WIPO (PCT)
Prior art keywords
insect cells
cancer
cells containing
mammals
compositions
Prior art date
Application number
PCT/US2000/007200
Other languages
French (fr)
Other versions
WO2000055345A2 (en
WO2000055345A9 (en
Inventor
Isaiah J Fidler
Zhongyun Dhong
Weixin Lu
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority to EP00919463A priority Critical patent/EP1165818A2/en
Priority to JP2000605762A priority patent/JP2002539221A/en
Priority to CA002368427A priority patent/CA2368427A1/en
Publication of WO2000055345A2 publication Critical patent/WO2000055345A2/en
Publication of WO2000055345A3 publication Critical patent/WO2000055345A3/en
Publication of WO2000055345A9 publication Critical patent/WO2000055345A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided are compositions and methods of use for insect cells comprising baculovirus encoding non-surface expressed proteins and peptides. The claimed invention particularly relates to compositions comprising insect cells containing baculovirus that express cytokines. Such compositions may be administered by, for example, direct intratumoral injection into tumors in mammals, resulting in tumor reduction or recission. Another aspect of the claimed invention concerns methods of promoting resistance to the reoccurrence of tumors in mammals who have undergone such tumor recission. In a specific aspect of the claimed invention, the mammals are human subjects presenting various forms of cancer.
PCT/US2000/007200 1999-03-17 2000-03-17 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes WO2000055345A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00919463A EP1165818A2 (en) 1999-03-17 2000-03-17 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
JP2000605762A JP2002539221A (en) 1999-03-17 2000-03-17 Treatment of cancer with insect cells containing the gene encoded by the recombinant baculovirus
CA002368427A CA2368427A1 (en) 1999-03-17 2000-03-17 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/271,013 US6342216B1 (en) 1999-03-17 1999-03-17 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US09/271,013 1999-03-17

Publications (3)

Publication Number Publication Date
WO2000055345A2 WO2000055345A2 (en) 2000-09-21
WO2000055345A3 true WO2000055345A3 (en) 2001-05-31
WO2000055345A9 WO2000055345A9 (en) 2001-06-21

Family

ID=23033818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007200 WO2000055345A2 (en) 1999-03-17 2000-03-17 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes

Country Status (5)

Country Link
US (1) US6342216B1 (en)
EP (1) EP1165818A2 (en)
JP (1) JP2002539221A (en)
CA (1) CA2368427A1 (en)
WO (1) WO2000055345A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535065A (en) 2000-05-31 2003-11-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Preparation of adjuvant for induction of specific immunity
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2002013861A2 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
AU2005211362B2 (en) 2004-02-02 2008-03-13 Ambrx, Inc. Modified human interferon polypeptides and their uses
CA2568952C (en) * 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
MX2007000728A (en) * 2004-07-21 2007-03-15 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids.
JP5425398B2 (en) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
JP4990792B2 (en) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド Compositions of aminoacyl-tRNA synthetases and uses thereof
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
ATE529442T1 (en) 2005-06-03 2011-11-15 Ambrx Inc IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc Methods and compositions comprising non-natural amino acids
MX2009002526A (en) 2006-09-08 2009-04-16 Ambrx Inc Suppressor trna transcription in vertebrate cells.
DK2061878T3 (en) 2006-09-08 2014-04-07 Ambrx Inc HYBRID SUPPRESSOR TRNA FOR ANIMAL CELLS
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
ATE554785T1 (en) 2007-03-30 2012-05-15 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US7661979B2 (en) * 2007-06-01 2010-02-16 Cooper Technologies Company Jacket sleeve with grippable tabs for a cable connector
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
US20090246226A1 (en) * 2008-03-28 2009-10-01 Zeon Corporation Avian vaccines possessing a positive marker gene
US7859849B2 (en) * 2008-05-14 2010-12-28 Finisar Corporation Modular heatsink mounting system
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
CN102232085A (en) 2008-09-26 2011-11-02 Ambrx公司 Modified animal erythropoietin polypeptides and their uses
MX2011003196A (en) 2008-09-26 2011-04-27 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines.
MX349301B (en) 2009-12-21 2017-07-21 Ambrx Inc Modified bovine somatotropin polypeptides and their uses.
BR112012015597A2 (en) 2009-12-21 2017-01-31 Ambrx Inc modified porcine somatotropin peptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (en) 2010-08-17 2021-12-28 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
CN103305469B (en) * 2013-05-28 2015-01-07 青岛农业大学 Serum-free culture adapted recombinant protein high-expression cell strain QB-Tn9-4S-Cl-F and application thereof
EA036697B1 (en) 2014-10-24 2020-12-09 Бристол-Майерс Сквибб Компани Modified fgf-21 polypeptides and uses thereof
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001038A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
WO1993007906A1 (en) * 1991-10-25 1993-04-29 San Diego Regional Cancer Center Lymphokine gene therapy of cancer
JPH06166635A (en) * 1992-06-18 1994-06-14 San Five Kk Immunoadjuvant
US5498540A (en) * 1994-02-23 1996-03-12 Sea Run Holdings, Inc. Method for culturing insect cells in a medium containing fish serum
WO1999024049A1 (en) * 1997-11-07 1999-05-20 Protein Sciences Corporation Insect cells or fractions as adjuvant for antigens
WO2000020561A1 (en) * 1998-10-08 2000-04-13 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
WO1995017515A1 (en) 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001038A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
WO1993007906A1 (en) * 1991-10-25 1993-04-29 San Diego Regional Cancer Center Lymphokine gene therapy of cancer
JPH06166635A (en) * 1992-06-18 1994-06-14 San Five Kk Immunoadjuvant
US5498540A (en) * 1994-02-23 1996-03-12 Sea Run Holdings, Inc. Method for culturing insect cells in a medium containing fish serum
WO1999024049A1 (en) * 1997-11-07 1999-05-20 Protein Sciences Corporation Insect cells or fractions as adjuvant for antigens
WO2000020561A1 (en) * 1998-10-08 2000-04-13 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LU W ET AL: "Eradication of primary tumors and induction of systemic immunity by an intralesional injection of baculovirus system-mediated interferon-beta gene therapy.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 41, March 2000 (2000-03-01), pages 470, XP000960443 *
MCCOWN J ET AL: "Protection of mice against lethal Japanese encephalitis with a recombinant baculovirus vaccine", AM J TROP MED HYG., vol. 42, no. 5, May 1990 (1990-05-01), pages 491 - 499, XP002916318 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 495 (C - 1250) 16 September 1994 (1994-09-16) *

Also Published As

Publication number Publication date
WO2000055345A2 (en) 2000-09-21
US6342216B1 (en) 2002-01-29
EP1165818A2 (en) 2002-01-02
WO2000055345A9 (en) 2001-06-21
CA2368427A1 (en) 2000-09-21
JP2002539221A (en) 2002-11-19

Similar Documents

Publication Publication Date Title
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
MX344216B (en) Genetic products differentially expressed in tumors and the use thereof.
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2002024640A3 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
WO2005115360A3 (en) Formulations of anti-pain agents and methods of using the same
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
WO2004016643A3 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004096159A3 (en) Saposin c-dops: a novel anti-tumor agent
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2003076631A3 (en) Genetic products differentially expressed in tumors and use thereof
WO2000056866A3 (en) Akt-3 nucleic acids, polypeptides, and uses thereof
WO2005026205A3 (en) Genetic products which are differentially expressed in tumours and use thereof
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-39, DESCRIPTION, REPLACED BY NEW PAGES 1-39; PAGES 40-47, CLAIMS, REPLACED BY NEW PAGES 40-47; PAGE 8/8, DRAWINGS, REPLACED BY A NEW PAGE 8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2368427

Country of ref document: CA

Ref country code: CA

Ref document number: 2368427

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 605762

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000919463

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000919463

Country of ref document: EP